Convelo Therapeutics is a clinical-stage biotechnology company developing novel therapeutics that promote remyelination and synaptic repair in neurological diseases. Founded based on discoveries from Case Western Reserve University, the company targets the molecular mechanisms that drive oligodendrocyte dysfunction and synaptic loss in multiple sclerosis, Parkinson's disease, and amyotrophic lateral sclerosis [1].
The company's platform addresses two interconnected pathological hallmarks of neurodegeneration: myelin degeneration and synaptic dysfunction. By targeting potassium channels on oligodendrocyte precursor cells (OPCs) and synaptic repair pathways, Convelo aims to restore the structural and functional integrity of the nervous system.
| Attribute | Details |
|---|---|
| Founded | 2017 |
| Headquarters | Cleveland, Ohio, USA |
| Focus | Remyelination, synaptic repair |
| Stage | Preclinical to Phase 1 |
| Founders | Dr. Edward Feldman's group, Case Western Reserve University |
| Investors | Not disclosed |
Convelo's lead mechanism targets voltage-gated potassium channels on oligodendrocyte precursor cells. OPCs express specific potassium channels (including Kir4.1 and Kv1.x family members) that regulate their membrane potential and differentiation capacity. In disease states, these channels become dysregulated, preventing OPCs from differentiating into mature, myelinating oligodendrocytes [2].
Mechanism:
The company's small molecule potassium channel blockers promote OPC differentiation through several pathways:
Preclinical Data:
In cuprizone-induced demyelination models, Convelo's compounds increased the number of mature oligodendrocytes and improved myelin integrity as assessed by electron microscopy and behavioral outcomes. The approach is particularly compelling because it works through the native differentiation pathway rather than imposing an artificial state.
Beyond remyelination, Convelo is developing approaches that directly address synaptic dysfunction in neurodegenerative diseases. These programs recognize that:
Synaptic Repair Approach:
Convelo's synaptic repair programs target the molecular machinery of synapse formation and maintenance, including:
CVL-354 is Convelo's lead clinical program, a potassium channel blocker that promotes oligodendrocyte differentiation and remyelination. The compound is being evaluated in Phase 1 clinical trials for multiple sclerosis, with parallel preclinical development for Parkinson's disease.
Clinical Development:
CVL-354 completed single ascending dose (SAD) and multiple ascending dose (MAD) cohorts in healthy volunteers, demonstrating:
PD-Specific Rationale:
In Parkinson's disease, myelin breakdown in the nigrostriatal pathway contributes to circuit dysfunction. The dopaminergic axons that project from the substantia nigra pars compacta to the striatum depend on intact myelin for efficient signal transmission. Remyelination of these axons, while not replacing lost dopaminergic neurons, may restore some circuit-level function and provide neuroprotective support to surviving neurons [3].
CVL-231 is a next-generation remyelination compound in preclinical development, optimized for enhanced CNS penetration and improved tolerability.
Convelo has active discovery-stage programs targeting synaptic repair mechanisms for Parkinson's disease and ALS:
Oligodendrocytes are the myelinating cells of the central nervous system, producing the myelin sheath that enables rapid saltatory conduction and provides metabolic support to axons. In Parkinson's disease and other neurodegenerative conditions, oligodendrocyte dysfunction contributes to circuit failure independent of primary neuronal loss [4].
Key Concepts:
Myelin Function Beyond Conduction:
Myelin provides critical trophic support to axons through:
Synaptic loss in Parkinson's disease occurs through multiple mechanisms that Convelo's programs aim to address:
The convergence of these mechanisms on synaptic integrity makes synaptic repair a compelling therapeutic strategy that addresses downstream consequences of PD pathology.
| Company | Approach | Stage | PD Relevance |
|---|---|---|---|
| Convelo | K+ channel / remyelination | Phase 1 | Addresses nigrostriatal myelin |
| Rodin | HDAC6 inhibition | Phase 1-2 | Microtubule / synaptic transport |
| Synaptic Therapeutics | Sigma-2 modulation | Preclinical | Direct synaptic protection |
| Lundbeck | PDE4B inhibition | Preclinical | Synaptic plasticity enhancement |
| AbbVie | TREM2 agonists | Phase 1-2 | Microglial synaptic support |
Chen Y, et al. Potassium channel blockade promotes oligodendrocyte differentiation. 2020. ↩︎
Trudler D, et al. Oligodendrocyte dysfunction in Parkinson's disease. 2023. ↩︎
Feldman EL, et al. Remyelination as a therapeutic target in neurodegenerative diseases. 2019. ↩︎